Can Aaripiprazole Normalize Yatrogenic Hyperprolactinemia?
Aripiprazole is a second generation atypical antipsychotic (AAP), with properties of partial dopamine agonist, used in schizophrenia, bipolar disorder and depression, among others. On the other hand, the side effects associated with AAP treatment are drug-specific, with hyperprolactinemia and metabolic syndrome being some of the most important. Hyperprolactinemia is an adverse effect with consequences both in the short term, alterations in gonadal function and parkinsonism, and in the long term, osteopenia-osteoporosis, metabolic syndrome and / or increased thromboembolic risk. Therefore, normalization or reduction of prolactinemia is sufficient to avoid them. According to our results, aripiprazole would be the ideal component for the combined treatment with those other antipsychotics that cause hyperprolactinemia, such as risperidone, reducing it and alleviating or eliminating the adverse effects derived from chronic hyperprolactinemia.